Since CRC-82 had relatively higher expression of BCl-2 and BCL-XL with modest BCL-W expression, it is a good model to develop PDXs and to generate organoids (ORC-82) to evaluate the efficacy of ABT-263. This evidence concerns the gene BCL2 and colorectal carcinoma.